The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 18-20 September 2024
The following summarizes some of the highlights from Day 2 of ECTRIMS 2024.
The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 18-20 September 2024
The following summarizes some of the highlights from Day 2 of ECTRIMS 2024.
The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 18-20 September 2024
Please note that the NeuroSens ECTRIMS 2024 Highlights slide resource, developed in collaboration with Dr. Daniel Selchen, BARLO MS Centre, Toronto, will be available as of October 10th, on request only. Make your request now by completing the online form. Industry members can also use this form to request to sponsor a NeuroSens post-ECTRIMS event (in-person or virtual). For more information, contact us at info@neuro-sens.com. Read More
The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – 18-20 September 2024
The following summarizes some of the highlights from Day 1 of ECTRIMS 2024.
A meta-analysis of 13 meta-analyses reports that cannabidiol (CBD) is effective for children and adolescents with seizures related to Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS) and tuberous sclerosis complex (TSC) (Borowicz-Reutt et al. Molecules 2024;29:1981). Read More
‘Burned-out MS’ (BOMS) is a term that has arisen recently in the multiple sclerosis literature. An early definition of BOMS described patients with a high EDSS score after a prolonged course of illness who had atrophy but no inflammatory activity on MRI (Bhatia & Singh. Ann Indian Acad Neurol 2019;22:131-136). The MS Association of America described BOMS as a form of inactive MS in which disease progression slows dramatically later in life. This is not a new phenotype since these definitions overlap with that of stable disease (not active/without progression) in the 2013 revisions (Lublin et al. Neurology 2014;83:278-286). The key difference and controversy is that BOMS presumes that no further MS-related progression will occur. Read More